by The global gene silencing market size was estimated to be around US$ 4.02 billion in 2023 and is projected to reach US$ 8.48 billion by 2033, indicating a CAGR of 7.80% from 2024 to 2033.
Key Points
- North America held the largest share of 44% in the market in 2023.
- On the other hand, Asia Pacific is observed to witness the fastest CAGR of 9.8% during the forecast period.
- By type, the transcriptional segment held the largest share of 53% in 2023 in the gene silencing market.
- On the other hand, the post-transcriptional segment is expected to witness a substantial growing CAGR of 8.8% during the forecasted period.
- By application, the neurological diseases treatment segment dominated the market with a 41% market share in 2023.
The Gene Silencing Market is a dynamic sector within the biotechnology and pharmaceutical industries that revolves around the modulation of gene expression to treat or prevent diseases. Gene silencing refers to the deliberate downregulation or suppression of specific genes, often achieved through techniques such as RNA interference (RNAi) or antisense oligonucleotides. This innovative field has garnered significant attention for its potential to address a wide range of genetic disorders and other diseases at the molecular level.
Get a Sample: https://www.precedenceresearch.com/sample/3774
Growth Factors
Several key factors contribute to the growth of the Gene Silencing Market. Advances in molecular biology and genomics have significantly expanded our understanding of disease pathways, enabling the identification of novel gene targets for therapeutic intervention. The rise of precision medicine and personalized treatments further propels the demand for gene silencing technologies, as they offer tailored solutions based on individual genetic profiles. Additionally, the increasing prevalence of genetic disorders and chronic diseases worldwide creates a substantial market opportunity for gene silencing therapies.
Gene Silencing Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 7.80% |
| Global Market Size in 2023 | USD 4.02 Billion |
| Global Market Size by 2033 | USD 8.48 Billion |
| U.S. Market Size in 2023 | USD 1.24 Billion |
| U.S. Market Size by 2033 | USD 2.66 Billion |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Type and By Application |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Fiber Optic Sensing System Market Size to Reach USD 7.23 Bn by 2033
Opportunities
The Gene Silencing Market presents numerous opportunities for innovation and market expansion. Ongoing research and development efforts focus on improving the efficiency and delivery methods of gene silencing technologies, enhancing their therapeutic efficacy. Collaborations between academic institutions, biotech companies, and pharmaceutical giants drive the discovery of new gene targets and the development of cutting-edge therapies. The growing interest in RNA-based therapeutics opens doors for the exploration of diverse applications, including oncology, neurodegenerative diseases, and rare genetic disorders.
Challenges
Despite its promising potential, the Gene Silencing Market faces challenges that require careful consideration. Delivery hurdles, such as efficiently transporting therapeutic agents to target cells or tissues, remain a significant obstacle. Off-target effects and potential immune responses also pose challenges in ensuring the safety and specificity of gene silencing interventions. Moreover, the high cost of research and development, along with regulatory complexities, can impede the timely translation of promising discoveries into approved therapies. Addressing these challenges is crucial for the sustained growth and success of the gene silencing industry.
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
Gene Silencing Market Companies
- Alnylam Pharmaceuticals (USA)
- Arrowhead Pharmaceuticals (USA)
- Dicerna Pharmaceuticals (USA)
- Ionis Pharmaceuticals (USA)
- Quark Pharmaceuticals (Israel)
- Benitec Biopharma (Australia)
- Sirnaomics (USA)
- Silence Therapeutics (United Kingdom)
- OliX Pharmaceuticals (South Korea)
- Arcturus Therapeutics (USA)
- Sylentis (Spain)
- Exicure (USA)
- miRagen Therapeutics (USA)
- Regulus Therapeutics (USA)
- Rxi Pharmaceuticals (USA)
Segments Covered in the Report
By Type
- Transcriptional
- Post-transcriptional
- Meiotic
By Application
- Cancer Treatment
- Neurological Diseases Treatment
- Scar Treatment
- Other
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Gene Silencing Market
5.1. COVID-19 Landscape: Gene Silencing Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Gene Silencing Market, By Type
8.1. Gene Silencing Market, by Type, 2024-2033
8.1.1. Transcriptional
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Post-transcriptional
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Meiotic
8.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Gene Silencing Market, By Application
9.1. Gene Silencing Market, by Application, 2024-2033
9.1.1. Cancer Treatment
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Neurological Diseases Treatment
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Scar Treatment
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Other
9.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Gene Silencing Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Type (2021-2033)
10.1.2. Market Revenue and Forecast, by Application (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Type (2021-2033)
10.1.3.2. Market Revenue and Forecast, by Application (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Type (2021-2033)
10.1.4.2. Market Revenue and Forecast, by Application (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Type (2021-2033)
10.2.2. Market Revenue and Forecast, by Application (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Type (2021-2033)
10.2.3.2. Market Revenue and Forecast, by Application (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Type (2021-2033)
10.2.4.2. Market Revenue and Forecast, by Application (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Type (2021-2033)
10.2.5.2. Market Revenue and Forecast, by Application (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Type (2021-2033)
10.2.6.2. Market Revenue and Forecast, by Application (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Type (2021-2033)
10.3.2. Market Revenue and Forecast, by Application (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Type (2021-2033)
10.3.3.2. Market Revenue and Forecast, by Application (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Type (2021-2033)
10.3.4.2. Market Revenue and Forecast, by Application (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Type (2021-2033)
10.3.5.2. Market Revenue and Forecast, by Application (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Type (2021-2033)
10.3.6.2. Market Revenue and Forecast, by Application (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Type (2021-2033)
10.4.2. Market Revenue and Forecast, by Application (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Type (2021-2033)
10.4.3.2. Market Revenue and Forecast, by Application (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Type (2021-2033)
10.4.4.2. Market Revenue and Forecast, by Application (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Type (2021-2033)
10.4.5.2. Market Revenue and Forecast, by Application (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Type (2021-2033)
10.4.6.2. Market Revenue and Forecast, by Application (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Type (2021-2033)
10.5.2. Market Revenue and Forecast, by Application (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Type (2021-2033)
10.5.3.2. Market Revenue and Forecast, by Application (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Type (2021-2033)
10.5.4.2. Market Revenue and Forecast, by Application (2021-2033)
Chapter 11. Company Profiles
11.1. Alnylam Pharmaceuticals (USA)
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Arrowhead Pharmaceuticals (USA)
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Dicerna Pharmaceuticals (USA)
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Ionis Pharmaceuticals (USA)
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Quark Pharmaceuticals (Israel)
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Benitec Biopharma (Australia)
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Sirnaomics (USA)
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Silence Therapeutics (United Kingdom)
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. OliX Pharmaceuticals (South Korea)
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Arcturus Therapeutics (USA)
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
